Linear and branched polyacrylates as a delivery platform for peptide-based vaccines.

AIM Peptide-based vaccines are designed to carry the minimum required antigen to trigger the desired immune responses; however, they are usually poorly immunogenic and require appropriate delivery system. RESULTS Peptides, B-cell epitope (J14) derived from group A streptococcus M-protein and universal T-helper (PADRE) epitope, were conjugated to a variety of linear and branched polyacrylates. All produced conjugates formed submicron-sized particles and induced a high level of IgG titres in mice after subcutaneous immunization. These polymer-peptide conjugates demonstrated high opsonization capacity against group A streptococcus clinical isolates. CONCLUSION We have successfully demonstrated that submicron-sized polymer-peptide conjugates were capable of inducing strong humoral immune responses after single immunization.

[1]  M. Skwarczynski,et al.  Peptide-based synthetic vaccines , 2015, Chemical science.

[2]  M. Skwarczynski,et al.  The Use of Microwave-Assisted Solid-Phase Peptide Synthesis and Click Chemistry for the Synthesis of Vaccine Candidates Against Hookworm Infection. , 2016, Methods in molecular biology.

[3]  M. Inouye,et al.  Post-infectious group A streptococcal autoimmune syndromes and the heart. , 2015, Autoimmunity reviews.

[4]  A. Steer,et al.  Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus , 2015, Journal of immunology research.

[5]  Christoph Meinel,et al.  A design thinking approach to effective vaccine safety communication. , 2015, Current drug safety.

[6]  W. M. Hussein,et al.  Self-adjuvanting therapeutic peptide-based vaccine induce CD8+ cytotoxic T lymphocyte responses in a murine human papillomavirus tumor model. , 2015, Current drug delivery.

[7]  W. M. Hussein,et al.  Polyacrylate-based delivery system for self-adjuvanting anticancer peptide vaccine. , 2015, Journal of medicinal chemistry.

[8]  Istvan Toth,et al.  Recent advances in peptide-based subunit nanovaccines. , 2014, Nanomedicine.

[9]  M. Skwarczynski,et al.  Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity. , 2014, Nanomedicine.

[10]  Timothy C. Barnett,et al.  Disease Manifestations and Pathogenic Mechanisms of Group A Streptococcus , 2014, Clinical Microbiology Reviews.

[11]  W. M. Hussein,et al.  Toll-like receptor agonists: a patent review (2011 – 2013) , 2014, Expert opinion on therapeutic patents.

[12]  M. Skwarczynski,et al.  Peptide Conjugation via CuAAC ′Click′ Chemistry , 2014 .

[13]  Istvan Toth,et al.  Recent progress in adjuvant discovery for peptide-based subunit vaccines , 2014, Human vaccines & immunotherapeutics.

[14]  M. Skwarczynski,et al.  Self-assembled peptide-polymer conjugates as vaccines , 2014 .

[15]  M. Skwarczynski,et al.  Polymer-peptide hybrids as a highly immunogenic single-dose nanovaccine. , 2014, Nanomedicine.

[16]  M. Skwarczynski,et al.  Peptide Conjugation via CuAAC ‘Click’ Chemistry , 2013, Molecules.

[17]  W. M. Hussein,et al.  Self-adjuvanting polymer-peptide conjugates as therapeutic vaccine candidates against cervical cancer. , 2013, Biomacromolecules.

[18]  L. Guilherme,et al.  StreptInCor: A Candidate Vaccine Epitope against S. pyogenes Infections Induces Protection in Outbred Mice , 2013, PloS one.

[19]  A. Ralph,et al.  Group a streptococcal diseases and their global burden. , 2013, Current topics in microbiology and immunology.

[20]  B. Williams,et al.  Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. , 2012, The Journal of infectious diseases.

[21]  M. Skwarczynski,et al.  Lipid Peptide Core Nanoparticles as Multivalent Vaccine Candidates against Streptococcus pyogenes , 2012 .

[22]  A. Revelas,et al.  Group A streptococcal infections in children , 2012 .

[23]  J. Carapetis,et al.  Rheumatic fever - identification, management and secondary prevention. , 2012, Australian family physician.

[24]  Michael J Monteiro,et al.  Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[25]  Michael J Monteiro,et al.  Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. , 2010, Angewandte Chemie.

[26]  T. Penfound,et al.  Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes. , 2010, Vaccine.

[27]  M. Cunningham.  Pathogenesis of group A streptococcal infections and their sequelae. , 2008, Advances in experimental medicine and biology.

[28]  James McCluskey,et al.  More than one reason to rethink the use of peptides in vaccine design , 2007, Nature Reviews Drug Discovery.

[29]  오윤석,et al.  Adjuvants , 2021, Visceral Leishmaniasis.

[30]  J. Carapetis,et al.  The global burden of group A streptococcal diseases. , 2005, The Lancet. Infectious diseases.

[31]  L. Hilgers,et al.  Alkyl-polyacrylate esters are strong mucosal adjuvants. , 2000, Vaccine.

[32]  D. Jackson,et al.  New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population , 2000, Nature Medicine.

[33]  S. Hoffman,et al.  Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites. , 1999, Vaccine.

[34]  E. Dewil,et al.  Alkyl-esters of polyacrylic acid as vaccine adjuvants. , 1998, Vaccine.

[35]  E L Kaplan,et al.  Why have group A streptococci remained susceptible to penicillin? Report on a symposium. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  S. Hoffman,et al.  Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. , 1997, Vaccine.

[37]  D. Baxby.  The Jenner bicentenary: the introduction and early distribution of smallpox vaccine. , 1996, FEMS immunology and medical microbiology.

[38]  D. Gardiner,et al.  Molecular epidemiology of impetiginous group A streptococcal infections in aboriginal communities of northern Australia , 1996, Journal of clinical microbiology.

[39]  L. Guilherme,et al.  Human heart-infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. , 1995, Circulation.

[40]  C Oseroff,et al.  Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. , 1994, Immunity.

[41]  Antonio Lanzavecchia,et al.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.

[42]  V. Fischetti,et al.  Streptococcal M protein: molecular design and biological behavior , 1989, Clinical Microbiology Reviews.

[43]  G. Stollerman.  RHEUMATIC FEVER , 1947, A.M.A. archives of internal medicine.